25th PAGE Meeting

Lisboa - Portugal
7-10 June, 2016

View abstracts

Home / 2016 – Lisboa – Portugal / Abstracts

← Back to filters

Abstracts (22)

I-07Yumi Yamamoto

Development of a generic model for brain distributional pharmacokinetics and its translation to clinical data

Wednesday 10:20-11:40

I-08Gregory Ferl

Mechanistic model of amyloid beta (Aß) and anti-Aß mAb dynamics

Wednesday 10:20-11:40

I-13Nicolas Frey

Model-based meta-analysis of amyloid plaque reduction in Alzheimer’s disease patients to identify new Phase 3 doses and dosing regimens for Gantenerumab

Wednesday 10:20-11:40

I-58Marija Jovanovic

Population pharmacokinetic model of topiramate and its major metabolite in adult epileptic patients

Wednesday 10:20-11:40

I-60Tatiana Karelina

Clinical trial simulation and hypothesis testing using amyloid pathology longitudinal translational model

Wednesday 10:20-11:40

I-69

A population disease progression model for Amyotrophic Lateral Sclerosis – Results of the Treeway Summer Challenge 2015

Wednesday 10:20-11:40

I-73Mary Lavy

Population Pharmacokinetics (PK) and Pharmacodynamics (PD) of Natalizumab in Patients with Multiple Sclerosis (MS)

Wednesday 10:20-11:40

II-03Malidi Ahamadi

Population exposure –response analysis of “On-Off” time in Individuals with Parkinson Disease following Preladenant Treatment

Wednesday 15:10-16:30

II-08Silvana Alvariza

Autoinduction of phenytoin hepatobiliary secretion as a mechanism for its nonlinear pharmacokinetics

Wednesday 15:10-16:30

II-26Irina Bondareva

External validation and predictability of nonlinear models for changes in steady–state pharmacokinetics (PK) of carbamazepine (CBZ) and valproate (VPA) due to antiepileptic drug-drug interactions using sparse therapeutic drug monitoring (TDM) data

Wednesday 15:10-16:30

II-53Valerie Cosson

Amyloid related imaging abnormalities (ARIA): Time to event modeling to identify new Phase 3 doses and dosing regimens for Gantenerumab

Wednesday 15:10-16:30

II-58Fabrizia D'Antonio

Effect of psychotic subtypes on cognitive trajectories in Alzheimer’s disease Neuroimaging Initiative ADNI2.

Wednesday 15:10-16:30

III-03Andreas Lindauer

Time-to-seizure modeling of the antiepileptic drug lacosamide used in monotherapy

Thursday 10:05-11:30

III-16Amelie Marsot

Population pharmacokinetic model of delta-9-tetrahydrocannabinol (THC) in cannabis occasional smokers

Thursday 10:05-11:30

III-43Theodoros Papathanasiou

Population modelling of the synergistic effects of morphine and gabapentin in the rat: a response surface approach

Thursday 10:05-11:30

III-66Su-jin Rhee

A population pharmacokinetic analysis of levetiracetam in patients with epilepsy

Thursday 10:05-11:30

IV-20Eva Sverrisdottir

Pharmacokinetic Metamodel of Morphine and Morphine-6-Glucuronide in Neonates and Adults

Thursday 14:40-16:00

IV-23Paulo Teixeira

The Effect of Anthropometric Covariates on Clearance of Valproic Acid.

Thursday 14:40-16:00

IV-36Iñaki F. Trocóniz

Markov Model for Lithium Compliance Assessment

Thursday 14:40-16:00

IV-37Max Tsai

Modelling of Pharmacokinetics and the Incidence of Adverse Events of the PDE-10A Inhibitor TAK-063

Thursday 14:40-16:00

IV-44Sven van Dijkman

Differentiation between Parkinson’s and Parkinson’s-like patients in MDS-UPDRS-based diagnosis

Thursday 14:40-16:00

IV-69Seonghae Yoon

Population pharmacokinetic analysis of oxcarbazepine in patients with epilepsy

Thursday 14:40-16:00